PCRX - Pacira BioSciences Non-GAAP EPS of $0.80 misses by $0.03 revenue of $172M misses by $1.32M

• Pacira BioSciences press release ( NASDAQ: PCRX ): Q4 Non-GAAP EPS of $0.80 misses by $0.03 .
• Revenue of $172M (+8.0% Y/Y) misses by $1.32M .
• Pacira ended the fourth quarter of 2022 with cash, cash equivalents and available-for-sale investments (“cash”) of $325.9 million. Cash provided by operations was $42.0 million in the fourth quarter of 2022, compared to $23.2 million in the fourth quarter of 2021.
• Adjusted EBITDA was $58.8 million in the fourth quarter of 2022, a 15% decrease compared to $69.3 million in the fourth quarter of 2021.

• 2023 Financial Guidance:

  • EXPAREL net product sales of $570 million to $580 million;
  • ZILRETTA net product sales of $115 million to $125 million;
  • iovera° net product sales of $17 million to $20 million;
  • Non-GAAP Gross margin of 76% to 78%;
  • Non-GAAP R&D expense of $70 million to $80 million;
  • Non-GAAP SG&A expense of $220 million to $230 million; and
  • Stock-based compensation of $51 million to $54 million.

For further details see: